SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Gorman, C
Right arrow Articles by Isenberg, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorman, C
Right arrow Articles by Isenberg, D
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lupus
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus?

C Gorman

Centre for Rheumatology, The Middlesex Hospital, University College London, UK

M Leandro

Centre for Rheumatology, The Middlesex Hospital, University College London, UK

D Isenberg

Centre for Rheumatology, The Middlesex Hospital, University College London, UK, d.isenberg{at}ud.ac.uk

B cell dysfunctionand pathogenicautoantibodyformationare thoughtto be criticalin the pathogenesis of systemic lupus erythematosus (SLE). In this review we will summarize the results of attempts to utilize B cell depletion, based on the use of a chimeric monoclonalantibody(MAb) specific for human CD20, rituximab, for the treatment of patients with SLE.

Key Words: anti-CD20 • rituximab • systemic lupus erythematosus

Lupus, Vol. 13, No. 5, 312-316 (2004)
DOI: 10.1191/0961203304lu1018oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
D Albert, J Dunham, S Khan, J Stansberry, S Kolasinski, D Tsai, S Pullman-Mooar, F Barnack, C Striebich, R J Looney, et al.
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus
Ann Rheum Dis, December 1, 2008; 67(12): 1724 - 1731.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. J. Leandro, G. Cambridge, J. C. Edwards, M. R. Ehrenstein, and D. A. Isenberg
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients
Rheumatology, December 1, 2005; 44(12): 1542 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
S Vasoo and G R. Hughes
Theory, targets and therapy in systemic lupus erythematosus
Lupus, March 1, 2005; 14(3): 181 - 188.
[Abstract] [PDF]

Home page
 LupusHome page
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas
Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus
Lupus, December 1, 2004; 13(12): 887 - 890.
[PDF]


Advertisement